Kirsten Bockstaele - Sequana Medical Chief Officer
| SEQUA Stock | 0.89 0.03 3.49% |
Insider
Kirsten Bockstaele is Chief Officer of Sequana Medical NV
| Age | 48 |
| Phone | 32 9 298 28 28 |
| Web | https://www.sequanamedical.com |
Sequana Medical Management Efficiency
The company has return on total asset (ROA) of (0.5412) % which means that it has lost $0.5412 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (2.2237) %, meaning that it generated substantial loss on money invested by shareholders. Sequana Medical's management efficiency ratios could be used to measure how well Sequana Medical manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Susy Spruyt | Biocartis Group NV | 55 | |
| Piet Houwen | Biocartis Group NV | 55 | |
| Renate Degrave | Biocartis Group NV | N/A | |
| Arjen MSc | Argen X | 38 | |
| Dirk Zimmermann | Biocartis Group NV | N/A | |
| Pr Ir | Argen X | 63 | |
| Benoit Devogelaere | Biocartis Group NV | 42 | |
| EMBA MBA | Argen X | 50 | |
| Malini Moorthy | Argen X | 53 | |
| Keith Woods | Argen X | 55 | |
| Reginald Genechten | Biocartis Group NV | 57 | |
| Erwin Sablon | Biocartis Group NV | 58 | |
| Karl Gubitz | Argen X | 53 | |
| Geert Maertens | Biocartis Group NV | N/A | |
| JeanMarc Roelandt | Biocartis Group NV | 58 | |
| Beth DelGiacco | Argen X | N/A | |
| Andria Wilk | Argen X | 49 | |
| Filip Borgions | Argen X | N/A | |
| Herman Verrelst | Biocartis Group NV | 49 | |
| David MD | Argen X | 71 | |
Management Performance
| Return On Equity | -2.22 | |||
| Return On Asset | -0.54 |
Sequana Medical NV Leadership Team
Elected by the shareholders, the Sequana Medical's board of directors comprises two types of representatives: Sequana Medical inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Sequana. The board's role is to monitor Sequana Medical's management team and ensure that shareholders' interests are well served. Sequana Medical's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Sequana Medical's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Lies Vanneste, Director Relations | ||
| Ian Crosbie, CEO Director | ||
| Martijn Blom, Chief Officer | ||
| Kirsten Bockstaele, Chief Officer | ||
| Oliver MD, Chief Officer | ||
| Gijs Klarenbeek, Chief Officer |
Sequana Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Sequana Medical a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -2.22 | |||
| Return On Asset | -0.54 | |||
| Current Valuation | 134.46 M | |||
| Shares Outstanding | 23.75 M | |||
| Shares Owned By Insiders | 13.66 % | |||
| Shares Owned By Institutions | 53.97 % | |||
| Price To Book | 11.52 X | |||
| Price To Sales | 182.39 X | |||
| Revenue | 370.5 K | |||
| Gross Profit | 718 K |
Pair Trading with Sequana Medical
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Sequana Medical position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Sequana Medical will appreciate offsetting losses from the drop in the long position's value.Moving against Sequana Stock
The ability to find closely correlated positions to Sequana Medical could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Sequana Medical when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Sequana Medical - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Sequana Medical NV to buy it.
The correlation of Sequana Medical is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Sequana Medical moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Sequana Medical NV moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Sequana Medical can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Other Information on Investing in Sequana Stock
Sequana Medical financial ratios help investors to determine whether Sequana Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Sequana with respect to the benefits of owning Sequana Medical security.